We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PHOE:TASEPhoenix Financial Ltd Analysis

Data as of 2026-03-14 - not real-time

$15.30

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Phoenix Asia Holdings is trading around $15.30, which is dramatically above its DCF‑derived fair value of roughly $1.90 and carries a trailing P/E near 300× versus an industry average of about 30×, indicating severe overvaluation. Technical indicators are mixed: RSI sits at a neutral 48, the MACD histogram is modestly positive suggesting a slight bullish tilt, and the price is comfortably above the calculated support of $10.36 but well below the resistance near $22.66. Volume trends are weakening, and short interest is minimal at just 0.31% of float, implying limited immediate selling pressure.
Fundamentally, the company posts solid growth metrics with revenue up 29% YoY, strong gross (≈30%) and operating margins (≈15%), and an impressive ROE above 40%, supported by ample cash and negligible debt. However, the stock pays no dividend, exhibits extreme 30‑day volatility (over 900%) and an anomalous negative beta, and liquidity is deteriorating, all of which amplify risk. The combination of lofty valuation, decent earnings quality, and heightened market risk leads to a cautious outlook: short‑term hold, medium‑term sell, and a long‑term hold contingent on a price correction.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Neutral technical stance with modest bullish MACD signal
  • Severe overvaluation relative to fundamentals
  • Low short interest and decreasing volume

Medium Term

1–3 years
Cautious
Model confidence: 6/10

Key Factors

  • Persistently high valuation multiples
  • Extreme price volatility and negative beta
  • Weakening liquidity and limited upside potential

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong earnings quality and growth trajectory
  • Potential for price correction to align with intrinsic value
  • Continued exposure to high market and liquidity risk

Key Metrics & Analysis

Financial Health

Revenue Growth29.30%
Profit Margin13.93%
P/E Ratio305.9
ROE42.60%
ROA17.88%
Debt/Equity0.81
P/B Ratio98.0
Op. Cash Flow$1.2M
Free Cash Flow$1.1M
Industry P/E29.1

Technical Analysis

TrendNeutral
RSI48.4
Support$10.36
Resistance$22.66
MA 20$15.47
MA 50$17.35
MA 200$12.73
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair Value$1.92
GradeOvervalued
TypeGrowth

Risk Assessment

Beta-4.48
Volatility938.12%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.